Funobactam is an investigational new drug that is being evaluated for the treatment of hospital-acquired bacterial pneumonia.[1] It is a β-lactamase inhibitor.[2]
Clinical data | |
---|---|
Other names | XNW-4107 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C13H17N7O6S |
Molar mass | 399.38 g·mol−1 |
3D model (JSmol) | |
| |
|
References
edit- ^ Clinical trial number NCT05204563 for "Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2) (REITAB-2)" at ClinicalTrials.gov
- ^ Marino A, Augello E, Stracquadanio S, Bellanca CM, Cosentino F, Spampinato S, et al. (June 2024). "Unveiling the Secrets of Acinetobacter baumannii: Resistance, Current Treatments, and Future Innovations". International Journal of Molecular Sciences. 25 (13): 6814. doi:10.3390/ijms25136814. PMC 11241693. PMID 38999924.